Ekos
Founded Year
1995Stage
Acquired | AcquiredTotal Raised
$85.1MValuation
$0000Missing: Ekos's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Ekos's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Ekos
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Ekos is included in 1 Expert Collection, including Medical Devices.
Medical Devices
3,088 items
Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)
Ekos Patents
Ekos has filed 56 patents.
The 3 most popular patent topics include:
- Medical ultrasonography
- Ultrasound
- Medical equipment
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/10/2012 | 10/4/2022 | Medical ultrasonography, Sensors, Medical equipment, Vascular diseases, Hematology | Grant |
Application Date | 5/10/2012 |
|---|---|
Grant Date | 10/4/2022 |
Title | |
Related Topics | Medical ultrasonography, Sensors, Medical equipment, Vascular diseases, Hematology |
Status | Grant |
Latest Ekos News
Jan 13, 2023
Ekos is a comprehensive solution that helps wineries track data across production, inventory, sales, and accounting. With Ekos, you’ll save time, improve visibility, and understand your costs (for real). Visit […] The post Learn Why Ekos Is Better Than Spreadsheets and Notebooks appeared first on Wine Industry Advisor.
Ekos Frequently Asked Questions (FAQ)
When was Ekos founded?
Ekos was founded in 1995.
Where is Ekos's headquarters?
Ekos's headquarters is located at 11911 N Creek Parkway South, Bothell.
What is Ekos's latest funding round?
Ekos's latest funding round is Acquired.
How much did Ekos raise?
Ekos raised a total of $85.1M.
Who are the investors of Ekos?
Investors of Ekos include BTG International, National Institutes of Health, CID Capital, NGN Capital, EGS Healthcare Capital Partners and 18 more.
Who are Ekos's competitors?
Competitors of Ekos include Brainsgate, Erydel, MicroCHIPS Biotech, NanoPass Technologies, Medipacs and 12 more.
Compare Ekos to Competitors
Cambridge Eyenovations is developing drug-eluting contact lenses that can dispense medicine automatically for glaucoma patients so that people don't need to put in eyedrops at all, and can go a month without changing contact lenses.
EryDel develops a red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases. Its proprietary technology relies upon the encapsulation of drugs into red cells taken from the patient's own blood, which are then re-infused into the patient.
EZRA Innovations currently holds exclusive worldwide rights in a controlled-release drug delivery system. Drug Surfactant Complex (DSC) Deoxycholate is used in combination with active pharmaceutical ingredients (API), DSC possesses the ability to change the chemical moiety of existing drugs and better extend release rates.
utilized "combinatorial chemistry" technology to discover lead therapeutic and diagnostic compounds.�MACUGEN, approved for wet age-related macular degeneration, was discovered using this technology. Upon NeXagen's merger with Vestar, Inc., the company also marketed and developed liposomal drug delivery products.
Berkeley Advanced Biomaterials Inc. (BAB) specializes in developing and manufacturing hydroxyapatite (HAP), tricalcium phosphate (TCP), and other calcium-based products. The company's activities are focussed on synthetic bone graft substitutes, sustained-release drug delivery devices, and applications of HAP for protein purification. The company's catalog offers a large variety of products with tailored morphologies and microstructures to match their needs for orthopedic surgery, bone tissue engineering, and life science research. Cem-Ostetic and Bi-Ostetic bone void fillers are approved for sale in the USA and the European Community.
Launched in July of 2000, the Westfield Life Sciences Fund invests in healthcare companies across the capitalization spectrum including medical devices, drugs, drug delivery, biotechnology, and healthcare services. Portfolio manager Will Muggia employs a fundamental, bottom up research driven process that focuses on preservation of capital and long-term outperformance. Westfield's industry network developed by Mr. Muggia and his analytical team is critical to new idea generation.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.